These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31665670)

  • 21. Self-Assembly of All-Inclusive Allochroic Nanoparticles for the Improved ELISA.
    Jiao L; Yan H; Xu W; Wu Y; Gu W; Li H; Du D; Lin Y; Zhu C
    Anal Chem; 2019 Jul; 91(13):8461-8465. PubMed ID: 31144813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
    Parise CA; Caggiano V
    Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between microRNA-21, microRNA-206 and estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 in breast cancer.
    Chen Y; Wu N; Liu L; Dong H; Wu C
    Clin Biochem; 2019 Sep; 71():52-57. PubMed ID: 31276668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
    Zhu Y; Guo M; Zhang L; Xu T; Wang L; Xu G
    Oncol Rep; 2016 Jan; 35(1):454-62. PubMed ID: 26531769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
    Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
    Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance of women with a personal history of breast cancer by tumour subtype.
    Benveniste AP; Dryden MJ; Bedrosian I; Morrow PK; Bassett RL; Yang W
    Clin Radiol; 2017 Mar; 72(3):266.e1-266.e6. PubMed ID: 28341031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.
    Tan LD; Xu YY; Yu Y; Li XQ; Chen Y; Feng YM
    PLoS One; 2011 Apr; 6(4):e18764. PubMed ID: 21533253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients.
    Zhang X; Hofmann S; Rack B; Harbeck N; Jeschke U; Sixou S
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
    Serra P; Sanz-Santos J; Castellà E; Cirauqui B; Andreo F; Llatjós M; Avila M; Margelí M; Serrano L; Centeno C; Quiroga V; Torky M; Ruiz-Manzano J
    Cytopathology; 2018 Feb; 29(1):35-40. PubMed ID: 29119620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of persistent organic pollutants in serum and adipose tissue with breast cancer prognostic markers.
    Arrebola JP; Fernández-Rodríguez M; Artacho-Cordón F; Garde C; Perez-Carrascosa F; Linares I; Tovar I; González-Alzaga B; Expósito J; Torne P; Fernández MF; Olea N
    Sci Total Environ; 2016 Oct; 566-567():41-49. PubMed ID: 27213669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients.
    Niedźwiecki S; Piekarski J; Szymańska B; Pawłowska Z; Jeziorski A
    Ginekol Pol; 2018; 89(8):415-420. PubMed ID: 30215459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
    Nwafor CC; Keshinro SO
    Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving accuracy of breast cancer biomarker testing in India.
    Shet T
    Indian J Med Res; 2017 Oct; 146(4):449-458. PubMed ID: 29434058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
    Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.